Related Experiment Video
Updated: May 11, 2026

Hydra, a Computer-Based Platform for Aiding Clinicians in Cardiovascular Analysis and Diagnosis
Published on: September 26, 2018
Conference report from the 2012 AHA scientific sessions in Los Angeles
B Daan Westenbrink1, Andrew G Edwards, Shigeki Miyamoto
1University Medical Center Groningen, Department of Cardiology and Pharmacology , Hanzeplein 1, P.O. Box 30001, 9700 RB Groningen , The Netherlands. b.d.westenbrink@umcg.nl
Insights
Highlights from the 2012 American Heart Association Scientific Sessions included new insights into arrhythmias and cardiac cell death/survival. The meeting also showcased novel treatment paradigms in clinical cardiology research.
Area of Science:
- Cardiovascular Science
- Clinical Cardiology
- Basic Science Research
Background:
- The 2012 American Heart Association Scientific Sessions convened to present the latest advancements in cardiovascular science.
- The conference focused on both fundamental research and clinical applications in cardiology.
Abstract:
The 2012 Scientific Sessions of the American Heart Association was held on November 3 - 7 in Los Angels, California. It covered up-to-date research on both basic- and clinical-cardiovascular science. We describe the highlights of the meeting focusing on basic science and clinical cardiology. More specifically we will discuss new insights on arrhythmias, cardiac cell death/survival and clinical studies involving novel and unique treatment paradigms.
Related Concept Videos
Types of Reports II: Incident or Occurrence Report
Purposes:
In the healthcare industry, reports play a crucial role in documenting incidents within an agency. The primary objective of these reports is to ensure patient safety, uphold the...
Types of Reports I: Hand-off Report
Following are the key components and categories of hand-off reports:
Purpose and Process:
Data Reporting and Recording
Acute Coronary Syndrome III: Diagnostic Studies
Heart Failure Drugs: Inhibitors of Renin-Angiotensin System
Antihypertensive Drugs: Angiotensin II Receptor Blockers

